Showing 2637 results
- Media Release /New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a…
- Media Release /Alcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase…
- Key Release /Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…
- Media Release /Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only…
- Key Release /Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
- Media Release /Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection…
- Media Release /Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week…
- Key Release /Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
- Media Release /Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
- Media Release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
Pagination
- ‹ Previous page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- …
- 264
- › Next page